In the murine B16 melanoma model, Zingg et al. demonstrated that an EZH2 inhibitor (GSK503) combined with IL-2 complexed with an anti-IL-2 monoclonal antibody (NARA1) or anti-CTLA-4 therapy, reduced tumor growth (49). Here, IL2 is linked to melanoma.